Research & Development

GlycoMimetics, Apollomics announce collaboration and license agreement for GMI-1687

GlycoMimetics and Apollomics announced an exclusive collaboration and license agreement for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

Merck enters into $2.5bn oncology deal with Taiho and Astex

Merck has joined hands with Japan’s Taiho Pharmaceutical and the UK’s Astex Pharmaceuticals in an oncology collaboration worth $2.5bn.

Leap Therapeutics and BeiGene announce exclusive option and license agreement for DKN-01

Leap Therapeutics has announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand.

Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics

Acceleron Pharma has entered into a pulmonary research and discovery collaboration agreement with Fulcrum Therapeutics.

Achillion shareholders approve agreement to be acquired by Alexion

Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals.

Organovo and Tarveda Therapeutics announce definitive merger agreement

Organovo Holdings and Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction.

Charles River Laboratories to buy HemaCare for $380m

Charles River Laboratories International has agreed to acquire human-derived cellular products provider HemaCare for around $380m in cash.

3M to sell drug delivery business to Altaris Capital Partners in $650m deal

3M, a US-based manufacturing company, has agreed to sell almost all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650m.

Retrogenix and Resonant Therapeutics announce strategic alliance to identify targets of anti-tumour antibodies

UK-based biotechnology company Retrogenix and US-based Resonant Therapeutics, Inc. announced today that they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.